Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nelistotug - GSK

Next Previous
Drug Profile

Nelistotug - GSK

Alternative Names: GSK-6097608; GSK’608; GSK’608 CD96

Latest Information Update: 30 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer 23andMe; GSK
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD96 antigen inhibitors; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer; Squamous cell cancer
  • No development reported Solid tumours

Most Recent Events

  • 13 May 2025 GlaxoSmithKline discontinues a phase II trial in Squamous cell carcinoma of head and neck (Metastatic disease) in USA, Argentina, Brazil, Canada, Denmark, Finland, France, Germany, Greece, Hungary, Italy, Japan, South Korea, Norway, Poland, Portugal, Romania, Spain, Sweden, Taiwan and Turkey due to the unsatisfactory results (NCT06062420)
  • 28 Sep 2024 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in Canada (IV, Infusion)
  • 02 May 2024 GlaxoSmithKline completes a phase-II clinical trial in Non-small cell lung cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA, Canada, Germany, France, Italy, Netherlands, South Korea, Poland, Romania, Russia, Spain and Sweden (Parenteral) (NCT03739710) (EudraCT2018-001316-29)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top